During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.
Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia / E. Palomba, M. Carrabba, G. Zuglian, L. Alagna, P. Saltini, V. Fortina, C. Hu, A. Bandera, G. Fabio, A. Gori, A. Muscatello. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 110:(2021 Sep), pp. 338-340. [10.1016/j.ijid.2021.07.064]
Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia
E. Palomba
Primo
;P. Saltini;V. Fortina;C. Hu;A. Bandera;G. Fabio;A. GoriPenultimo
;
2021
Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S1201971221006196-main.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
603.49 kB
Formato
Adobe PDF
|
603.49 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
